

**Area Drugs and Therapeutics Committee Meeting Minutes**

**Wednesday 21<sup>st</sup> August 2024 10-12pm**

Microsoft Teams Meeting

<b>Present:</b>	Mehrdad Malekian (Chair) Victoria Gemmell (Minutes) Chris Miller Colin Angus Tyra Smyth Lucy Reilly Christine Carswell (from item 6)	Rachael Kelly Stephanie Dundas Kirsty Macfarlane Graeme Bryson Craig Thurtell David Semple Gail Richardson
<b>1. Apologies:</b>	Penny Brankin Mark Kirk Alistair Brown	
<b>2. Declaration of Interest</b>	<b>Nil declared</b>	

--	--	--

Item	Notes	Action
<b>3.</b>	<b><u>Minutes/Actions from the last meeting</u></b> These were agreed as a true reflection of the meeting and can be published.	
<b>4.</b>	<b><u>Matters Arising</u></b>	
a)	<b>Asthma Biologics – update awaited Andrew Smith</b>	
b)	<b>Bimekizumab protocol – update awaited Sanjiv Nandwani</b>	
c)	<b>Gastroscopy - Audrey McCallum</b> These were accepted pending a small change. The guideline is to be shared via RDS.	
d)	<b>Heart Failure - Update Mehrdad Malekian</b> The updated guideline was reviewed. There were some comments about further changes and additions to content although changes requested on more than one occasion had already been actioned by author. The chair will discuss with author and other specialist colleagues and feedback to the group.	
e)	<b>Maternity Varicella in pregnancy guideline – Update awaited Hannah Fulton</b>	
f)	<b>Paediatric PCA / Postop Pain Guideline – update awaited Sharon Anderson</b>	

<p>5.</p>	<p><b><u>SMC Advice</u>-CONFIDENTIAL</b></p> <p>Please see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website <b>after 10.00 am on Monday 09 September 2024.</b></p> <p><b><u>Full Submissions</u></b></p> <ul style="list-style-type: none"> <li>• teclistamab (Tecvayli) Janssen-Cilag Ltd SMC2668 <b>ACCEPTED with PAS Await WoSCAN advice</b></li> <li>• dabrafenib (Finlee) Novartis Pharmaceuticals UK Ltd SMC2667 <b>ACCEPTED with PAS Await WoSCAN advice</b></li> <li>• elranatamab (Elrexio) Pfizer Limited SMC2669 <b>ACCEPTED ON INTERIM BASIS with PAS Await WoSCAN advice</b></li> <li>• ivosidenib (Tibsovo) Servier Laboratories SMC2664 <b>ACCEPTED with PAS Await WoSCAN advice</b></li> </ul> <p><b><u>Non Submissions</u></b></p> <ul style="list-style-type: none"> <li>• pegcetacoplan (Aspaveli) Swedish Orphan Biovitrum Ltd SMC2715</li> <li>• volanesorsen (Waylivra) Akcea Therapeutics UK Ltd SMC2716</li> <li>• zilucoplan (Zilbrysq) UCB Pharma Limited SMC2717</li> </ul> <p><b><u>Paediatric Licence Extensions</u></b> This was noted</p>	
<p>6.</p>	<p><b><u>SMC follow up</u></b></p> <p>RK detailed which SMC medications were reaching deadline and proposed plans for ongoing follow up which was agreed. Following advice received by local clinical experts, RK explained and got agreement on an ongoing plan for reaching a decision of designation for etranacogene dezaparovec (Hemgenix) SMC2649. Updates were given on updating designation for rimegepant (Vydua) SMC2521 - discussions ongoing. Designation decision for tirzepatide (Mounjaro) SMC2563 was discussed and is progressing.</p>	
<p>7.</p>	<p><b><u>Lanarkshire Formulary</u></b></p> <p><b>Formulary Amendment Form - June Currie</b> This was discussed in conjunction with item 8a below.</p> <p><b>Lizinna Formulary Amendment Form – Rachael Kelly</b> This was submitted following long term stock issues with Cilique. This was agreed with no changes. The formulary webpage will be updated accordingly</p> <p><b>Plenvu Formulary Amendment Form-Rachael Kelly</b> This was agreed with no changes. The formulary webpage will be updated accordingly</p> <p><b>Formulary Amendment-Continuous Glucose Monitoring-Rachael Kelly</b> This was agreed with no changes. The formulary webpage will be updated accordingly</p>	

	<p><b>Formulary Amendment-DPP4 Inhibitors-Rachael Kelly</b> This was agreed with no changes. The formulary webpage will be updated accordingly</p> <p><b>Proposed Amendments – Rachael Kelly</b> These comprised addition of statements informing of formulary products which have been discontinued or are in short supply. Work is underway in light of this. These were agreed with no changes. The formulary webpage will be updated accordingly</p> <p><b>Additional Item-Migraine Prophylaxis</b> This was agreed</p>	
<p><b>8.</b></p>	<p><b><u>Clinical Protocols</u></b></p> <p><b>(a) Use of Tirzepatide in NHSL approvals - June Currie</b> This was discussed. The committee asks for guidance as to preference for which agents, as several are now recommended for use in this patients group, and a clinical pathway would support this. The documents are not approved at this time.</p> <p><b>(b) Neurology Valproate pathway - Adam Daly</b> The committee welcomed this draft document. Some comments to be fed back to the authors. It was agreed that the final document should be shared widely. Clarify where to be held.</p> <p><b>(c) COPD Guidelines - Manish Patel</b> The committee felt this was a welcome update to previous guidance, and was approved with no changes.</p> <p><b>(d) SGLT2i Guideline &amp; Empagliflozin Protocol CKD Jack Fairweather</b> A small change was requested. Approved pending this change.</p> <p><b>(e) Avacoapan Guideline - Jack Fairweather</b> Approved with no further changes</p> <p><b>(f) Opicapone Clinical Protocol - Laura Peacock</b> The protocol was approved. The committee suggested that the NBM policy to be updated to reflect this.</p> <p><b>(g) Management of Periop Adult Diabetic guideline – Claire Carson</b> Some changes were requested. To be returned for final review.</p> <p><b>(h) Ritlecitinib – amended protocol update - Carole Martin</b></p>	

	The update to the protocol for this medicine was approved on clinical grounds by ADTC, and will proceed through standard procedures for evaluation and consideration of cost and service implications.	
9.	<b><u>ADTC New Medicines Decisions</u></b> These were noted. Bulletins comprised updates to designations as covered in Item 6.	
10. (a)	<b><u>Unlicensed Medicines</u></b> Nil	
11.	<b><u>Medication and Clinical risk in Lanarkshire</u></b> <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a> Epimax Drug Safety Update-this was noted	
12.	<b><u>Regional Cancer Advisory Network</u></b> Nil	
13.	<b><u>Patient Safety Alerts</u></b> <b>Quality Assurance Checklist Topiramate - Graeme Bryson</b> Topiramate has been added to the remit of the current Valproate SLWG, and will take forward necessary actions	
14.	<b><u>Lay member related items</u></b> Nil	
15. (a) (i)	<b><u>Correspondence</u></b> <b><u>ADTC Collaborative</u></b> Nil	
16.	<b>Pharmacy &amp; NMAHP Prescribing Governance</b> Nil	
17.	<b><u>AOCB</u></b> GR gave an update-the memo has been updated with some changes but committee agreed in principle. Planned switch for IV scheduled for September. Pabrinex stock will be redistributed within each site to areas of most need until supplies are exhausted and all areas move to UL product. GMAWS chart to be updated in due course.	
18.	<b><u>Date of next meeting</u></b> Wednesday 18 <sup>th</sup> September 2024 10-12pm MS TEAMS	